Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

“我们已经是第三次参加进博会了，过去几年借助进博会的平台，我们既能够分享我们的研发成果及业务进展，同时也在加速我们的创新产品在中国上市，尽早惠及更多群体。最后，我们也通过进博会的平台开展了多方合作，与各类伙伴签约，从而加速我们在中国发展的进程。”第七 ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...

医师报讯 ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...